LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: A Promising Biomarker and Therapeutic Target in Patients with Advanced PDAC

Journal of Personalized Medicine, Vol 12, Iss 623, p

The Stromal Protein βig-h3

2022 Volume 623

Abstract: With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late ... ...

Abstract	With an overall survival rate of 2–9% at 5 years, pancreatic ductal adenocarcinoma (PDAC) is currently the fourth leading cause of cancer-related deaths in the industrialized world and is predicted to become the second by 2030. Owing to often late diagnosis and rare actionable molecular alterations, PDAC has not yet benefited from the recent therapeutic advances that immune checkpoint inhibitors (ICI) have provided in other cancer types, except in specific subgroups of patients presenting with tumors with high mutational burden (TMB) or microsatellite instability (MSI). The tumor microenvironment (TME) plays a substantial role in therapeutic resistance by facilitating immune evasion. An extracellular stromal protein, βig-h3/TGFβi, is involved in the pathogenesis of PDAC by hampering T cell activation and promoting stiffness of the TME. The study BIGHPANC included 41 patients with metastatic PDAC, and analyzed βig-h3 levels in serum and tumor samples to assess the βig-h3 prognostic value. βig-h3 serum levels are significantly associated with overall survival (HR 2.05, 95%CI 1.07–3.93; p = 0.0301). Our results suggest that βig-h3 serum levels may be considered a prognostic biomarker in patients with metastatic PDAC.
Keywords	pancreatic adenocarcinoma ; pancreatic cancer ; BIGHPANC ; TGFbeta ; immune checkpoint inhibitors ; prognostic analysis ; Medicine ; R
Subject code	610 ; 616
Language	English
Publishing date	2022-04-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Systemic chemotherapy plus cetuximab after complete surgery in the treatment of isolated colorectal peritoneal carcinoma

Serge Evrard / Grégoire Desolneux / Carine Bellera / Thomas Esnaud / Yves Bécouarn / Denis Collet / Najim Chafai / Francois Marchal / Laurent Cany / Emilie Lermite / Michel Rivoire / Simone Mathoulin-Pélissier

BMC Research Notes, Vol 12, Iss 1, Pp 1-

COCHISE phase II clinical trial

2019 Volume 6

Abstract: Abstract Objective The primary objective of this non-randomised phase II study was to evaluate the combination of systemic chemotherapy plus cetuximab after complete cytoreductive surgery (CCS) for treatment of isolated colorectal peritoneal carcinoma ( ... ...

Abstract	Abstract Objective The primary objective of this non-randomised phase II study was to evaluate the combination of systemic chemotherapy plus cetuximab after complete cytoreductive surgery (CCS) for treatment of isolated colorectal peritoneal carcinoma (CRPC). This multicentre, prospective phase II clinical trial was conducted in seven national cancer referral centres, however research published during study recruitment indicated cetuximab treatment as ineffective in patients with mutated KRAS genes, leading to an additional exclusion criterion to the current protocol, excluding patients with mutated KRAS genes. This significantly impacted recruitment and the study did not achieve the necessary recruitment of 46 patients. Results Fourteen patients underwent CCS and were included in the study, however one did not provide informed consent and another received only one cycle of chemotherapy leading to 12 patients in the per protocol population for analysis. Adjuvant Folfox Cetuximab was administered when CCS was achieved for patients > 18 years with histologically proven CRPC and no other metastatic disease (liver, lungs, lymphadenopathy, etc.). CRPC median index was 5.00 (range: 1–17). Median PFS was 12.3 months [95% CI (3.7–28.2)] with 8.3% [95% CI (0.5–31.1)] and 0% PFS at 3 and 5 years respectively. Median OS was 43.4 months [95% CI (16.8–60)]. Trial registration Clinical Trials NCT00766142, October 3, 2008. Retrospectively registered
Keywords	Colorectal cancer ; Peritoneal carcinomatosis ; Cytoreductive surgery ; KRAS gene ; Hyperthermic intraperitoneal chemotherapy ; Medicine ; R ; Biology (General) ; QH301-705.5 ; Science (General) ; Q1-390
Subject code	610
Language	English
Publishing date	2019-07-01T00:00:00Z
Publisher	BMC
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: First clinical experience of intra-operative high intensity focused ultrasound in patients with colorectal liver metastases

Aurélien Dupré / David Melodelima / David Pérol / Yao Chen / Jérémy Vincenot / Jean-Yves Chapelon / Michel Rivoire

PLoS ONE, Vol 10, Iss 2, p e

a phase I-IIa study.

2015 Volume 0118212

Abstract: Surgery is the only curative treatment in patients with colorectal liver metastases (CLM), but only 10-20% of patients are eligible. High Intensity Focused Ultrasound (HIFU) technology is of proven value in several indications, notably prostate cancer. ... ...

Abstract	Surgery is the only curative treatment in patients with colorectal liver metastases (CLM), but only 10-20% of patients are eligible. High Intensity Focused Ultrasound (HIFU) technology is of proven value in several indications, notably prostate cancer. Its intra-operative use in patients with CLM has not previously been studied. Preclinical work suggested the safety and feasibility of a new HIFU device capable of ablating volumes of up to 2cm x 2cm in a few seconds.We conducted a prospective, single-centre phase I-IIa trial. HIFU was delivered immediately before scheduled hepatectomy. To demonstrate the safety and efficacy of rapidly ablating liver parenchyma, ablations were performed on healthy tissue within the areas scheduled for resection.In total, 30 ablations were carried out in 15 patients. These ablations were all generated within 40 seconds and on average measured 27.5mm x 21.0mm. The phase I study (n = 6) showed that use of the HIFU device was feasible and safe and did not damage neighbouring tissue. The phase IIa study (n = 9) showed both that the area of ablation could be precisely targeted on a previously implanted metallic mark (used to represent a major anatomical structure) and that ablations could be undertaken deliberately to avoid such a mark. Ablations were achieved with a precision of 1-2 mm.HIFU was feasible, safe and effective in ablating areas of liver scheduled for resection. The next stage is a phase IIb study which will attempt ablation of small metastases with a 5 mm margin, again prior to planned resection.ClinicalTrials.govNCT01489787.
Keywords	Medicine ; R ; Science ; Q
Subject code	616
Language	English
Publishing date	2015-01-01T00:00:00Z
Publisher	Public Library of Science (PLoS)
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Hepatitis B virus Core protein nuclear interactome identifies SRSF10 as a host RNA-binding protein restricting HBV RNA production.

PLoS Pathogens, Vol 16, Iss 11, p e

2020 Volume 1008593

Abstract: Despite the existence of a preventive vaccine, chronic infection with Hepatitis B virus (HBV) affects more than 250 million people and represents a major global cause of hepatocellular carcinoma (HCC) worldwide. Current clinical treatments, in most of ... ...

Abstract	Despite the existence of a preventive vaccine, chronic infection with Hepatitis B virus (HBV) affects more than 250 million people and represents a major global cause of hepatocellular carcinoma (HCC) worldwide. Current clinical treatments, in most of cases, do not eliminate viral genome that persists as a DNA episome in the nucleus of hepatocytes and constitutes a stable template for the continuous expression of viral genes. Several studies suggest that, among viral factors, the HBV core protein (HBc), well-known for its structural role in the cytoplasm, could have critical regulatory functions in the nucleus of infected hepatocytes. To elucidate these functions, we performed a proteomic analysis of HBc-interacting host-factors in the nucleus of differentiated HepaRG, a surrogate model of human hepatocytes. The HBc interactome was found to consist primarily of RNA-binding proteins (RBPs), which are involved in various aspects of mRNA metabolism. Among them, we focused our studies on SRSF10, a RBP that was previously shown to regulate alternative splicing (AS) in a phosphorylation-dependent manner and to control stress and DNA damage responses, as well as viral replication. Functional studies combining SRSF10 knockdown and a pharmacological inhibitor of SRSF10 phosphorylation (1C8) showed that SRSF10 behaves as a restriction factor that regulates HBV RNAs levels and that its dephosphorylated form is likely responsible for the anti-viral effect. Surprisingly, neither SRSF10 knock-down nor 1C8 treatment modified the splicing of HBV RNAs but rather modulated the level of nascent HBV RNA. Altogether, our work suggests that in the nucleus of infected cells HBc interacts with multiple RBPs that regulate viral RNA metabolism. Our identification of SRSF10 as a new anti-HBV restriction factor offers new perspectives for the development of new host-targeted antiviral strategies.
Keywords	Immunologic diseases. Allergy ; RC581-607 ; Biology (General) ; QH301-705.5
Subject code	570
Language	English
Publishing date	2020-11-01T00:00:00Z
Publisher	Public Library of Science (PLoS)
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes

Julie Lucifora / Marc Bonnin / Ludovic Aillot / Floriane Fusil / Sarah Maadadi / Laura Dimier / Maud Michelet / Océane Floriot / Anaïs Ollivier / Michel Rivoire / Malika Ait-Goughoulte / Stéphane Daffis / Simon P. Fletcher / Anna Salvetti / François-Loïc Cosset / Fabien Zoulim / David Durantel

Scientific Reports, Vol 8, Iss 1, Pp 1-

2018 Volume 11

Abstract: Abstract Current therapies for chronic hepatitis B virus (HBV) infections are effective at decreasing the viral load in serum, but do not lead to viral eradication. Recent studies highlighted the therapeutic or “adjuvant” potential of immune-modulators. ... ...

Abstract	Abstract Current therapies for chronic hepatitis B virus (HBV) infections are effective at decreasing the viral load in serum, but do not lead to viral eradication. Recent studies highlighted the therapeutic or “adjuvant” potential of immune-modulators. Our aim was to explore the direct anti-HBV effect of Toll-Like-Receptors (TLR) agonists in hepatocytes. HBV-infected primary human hepatocytes (PHH) or differentiated HepaRG cells (dHepaRG) were treated with various TLR agonists. Amongst all TLR ligands tested, Pam3CSK4 (TLR1/2-ligand) and poly(I:C)-(HMW) (TLR3/MDA5-ligand) were the best at reducing all HBV parameters. No or little viral rebound was observed after treatment arrest, implying a long-lasting effect on cccDNA. We also tested Riboxxol that features improved TLR3 specificity compared to poly(I:C)-(HMW). This agonist demonstrated a potent antiviral effect in HBV-infected PHH. Whereas, poly(I:C)-(HMW) and Pam3CSK4 mainly induced the expression of classical genes from the interferon or NF-κB pathway respectively, Riboxxol had a mixed phenotype. Moreover, TLR2 and TLR3 ligands can activate hepatocytes and immune cells, as demonstrated by antiviral cytokines produced by stimulated hepatocytes and peripheral blood mononuclear cells. In conclusion, our data highlight the potential of innate immunity activation in the direct control of HBV replication in hepatocytes, and support the development of TLR-based antiviral strategies.
Keywords	Medicine ; R ; Science ; Q
Subject code	570
Language	English
Publishing date	2018-03-01T00:00:00Z
Publisher	Nature Publishing Group
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer

Cells, Vol 8, Iss 6, p

A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

2019 Volume 516

Abstract: The management of patients with colorectal cancer (CRC) and potentially resectable liver metastases (LM) requires quick assessment of mutational status and of response to pre-operative systemic therapy. In a prospective phase II trial (NCT01442935), we ... ...

Abstract	The management of patients with colorectal cancer (CRC) and potentially resectable liver metastases (LM) requires quick assessment of mutational status and of response to pre-operative systemic therapy. In a prospective phase II trial (NCT01442935), we investigated the clinical validity of circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) detection. CRC patients with potentially resectable LM were treated with first-line triplet or doublet chemotherapy combined with targeted therapy. CTC (Cellsearch ® ) and Kirsten RAt Sarcoma (KRAS) ctDNA (droplet digital polymerase chain reaction (PCR)) levels were assessed at inclusion, after 4 weeks of therapy and before LM surgery. 153 patients were enrolled. The proportion of patients with high CTC counts (≥3 CTC/7.5mL) decreased during therapy: 19% (25/132) at baseline, 3% (3/108) at week 4 and 0/57 before surgery. ctDNA detection sensitivity at baseline was 91% (N=42/46) and also decreased during treatment. Interestingly, persistently detectable KRAS ctDNA ( p = 0.01) at 4 weeks was associated with a lower R0/R1 LM resection rate. Among patients who had a R0/R1 LM resection, those with detectable ctDNA levels before liver surgery had a shorter overall survival ( p < 0.001). In CRC patients with limited metastatic spread, ctDNA could be used as liquid biopsy tool. Therefore, ctDNA detection could help to select patients eligible for LM resection.
Keywords	circulating tumor cells ; circulating tumor DNA ; liquid biopsy ; metastatic colorectal cancer ; FOLFIRINOX ; Biology (General) ; QH301-705.5
Subject code	610 ; 616
Language	English
Publishing date	2019-05-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: High-intensity focused ultrasound ablation for the treatment of colorectal liver metastases during an open procedure: study on the pig.

Parmentier, Hubert / Hubert, Parmentier / Melodelima, David / David, Melodelima / N'Djin, Apoutou / Apoutou, N'Djin / Chesnais, Sabrina / Sabrina, Chesnais / Chapelon, Jean Yves / Yves, Chapelon Jean / Rivoire, Michel / Michel, Rivoire

Annals of surgery

2009 Volume 249, Issue 1, Page(s) 129–136

Abstract: Objective: To demonstrate in a porcine model that high-intensity focused ultrasound (HIFU) with toroid-shaped emitters may have a role in treating unresectable colorectal liver metastases.: Summary background data: Surgical resection is the only ... ...

Abstract	Objective: To demonstrate in a porcine model that high-intensity focused ultrasound (HIFU) with toroid-shaped emitters may have a role in treating unresectable colorectal liver metastases. Summary background data: Surgical resection is the only curative option for colorectal hepatic metastases. Only 20% of patients are suitable for surgery. Many ablative techniques have been assessed but several limitations have been documented: traumatic puncture of the parenchyma, limited size of lesions, and inability to monitor the treatment in real time. Methods: A HIFU device with 256 toroid-shaped emitters and integrated ultrasound imaging probe was used. Single lesions, induced in 40 seconds, and juxtaposition of 6 single lesions were created under ultrasound guidance on 13 pigs. The lesions were studied on sonograms, macroscopically and microscopically up to 30 days after the treatment. Results: Ninety percent of the HIFU lesions were immediately hypoechoic on ultrasound imaging. The average coagulated volume obtained from a 40 seconds total exposure in the liver was 7.0 +/- 2.5 cm (1.5-20.0), average diameter: 19.5 +/- 3.8 mm (10.0-29.0). Using the real-time visualization of the treated region, single lesions were easily juxtaposed to produce larger lesions up to 6 cm in diameter without any major complication. Conclusions: This toroid HIFU device allows short treatment times, noninvasiveness regarding the liver and real time ultrasound guidance. It seems to be simpler and more reliable to use than current ablative methods. Additionally, lesions through large vessels (up to 5 mm) being feasible, treatment of some juxta-vascular metastases should be possible.
MeSH term(s)	Animals ; Colorectal Neoplasms/pathology ; Equipment Design ; Liver/pathology ; Liver/surgery ; Liver Neoplasms/secondary ; Liver Neoplasms/surgery ; Liver Neoplasms/therapy ; Swine ; Ultrasonic Therapy/instrumentation
Language	English
Publishing date	2009-02-03
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	340-2
ISSN	1528-1140 ; 0003-4932
ISSN (online)	1528-1140
ISSN	0003-4932
DOI	10.1097/SLA.0b013e31818c70b6
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.35/1: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: 5th International Symposium on Focused Ultrasound

Menashe Zaaroor / Alon Sinai / Dorit Goldsher / Ayelet Eran / Maria Nassar / Ilana Schlesinger / Jonathon Parker / Vinod Ravikumar / Pejman Ghanouni / Sherman Stein / Casey Halpern / Vibhor Krishna / Amelia Hargrove / Punit Agrawal / Barbara Changizi / Eric Bourekas / Michael Knopp / Ali Rezai / Brian Mead /

Namho Kim / Panagiotis Mastorakos / Jung Soo Suk / Wilson Miller / Alexander Klibanov / Justin Hanes / Richard Price / Shutao Wang / Oluyemi Olumolade / Tara Kugelman / Vernice Jackson-Lewis / Maria Eleni (Marilena) Karakatsani / Yang Han / Serge Przedborski / Elisa Konofagou / Kullervo Hynynen / Isabelle Aubert / Gerhard Leinenga / Rebecca Nisbet / Robert Hatch / Anneke Van der Jeugd / Harrison Evans / Jürgen Götz / Ann Van der Jeugd / Paul Fishman / Paul Yarowsky / Victor Frenkel / Shen Wei-Bin / Ben Nguyen / Carlos Sierra Sanchez / Camilo Acosta / Cherry Chen / Shih-Ying Wu / Muna Aryal / Iason T. Papademetriou / Yong-Zhi Zhang / Chanikarn Power / Nathan McDannold / Tyrone Porter / Zsofia Kovacs / Saejeong Kim / Neekita Jikaria / Farhan Qureshi / Michele Bresler / Joseph Frank / Henrik Odéen / George Chiou / John Snell / Nick Todd / Bruno Madore / Dennis Parker / Kim Butts Pauly / Mike Marx / Sumeeth Jonathan / William Grissom / Costas Arvanitis / Gregory Clement / Joshua de Bever / Allison Payne / Douglas Christensen / Guillaume Maimbourg / Mathieu David Santin / Alexandre Houdouin / Stéphane Lehericy / Mickael Tanter / Jean Francois Aubry / Christian Federau / Beat Werner / Dong-Guk Paeng / Zhiyuan Xu / Anders Quigg / Matt Eames / Changzhu Jin / Ashli Everstine / Jason Sheehan / M. Beatriz Lopes / Neal Kassell / James Drake / Karl Price / Lior Lustgarten / Vivian Sin / Charles Mougenot / Elizabeth Donner / Emily Tam / Mojgan Hodaie / Adam Waspe / Thomas Looi / Samuel Pichardo / Wonhye Lee / Yong An Chung / Yujin Jung / In-Uk Song / Seung-Schik Yoo / Hyun-Chul Kim / Jong-Hwan Lee / Charles Caskey / Wolf Zinke / Josh Cosman / Jillian Shuman / Jeffrey Schall / Christian Aurup / Hong Chen / Hermes Kamimura / Antonio Carneiro / Tao Sun / Navid Nazai / Sam Patz / Margaret Livingstone / Todd Mainprize / Yuexi Huang / Ryan Alkins / Martin Chapman / James Perry / Nir Lipsman / Allison Bethune / Arjun Sahgal / Maureen Trudeau / Hao-Li Liu / Po-Hung Hsu / Kuo-Chen Wei / Jonathan Sutton / Phillip Alexander / Eric Miller / Thiele Kobus / Alexandre Carpentier / Michael Canney / Alexandre Vignot / Kevin Beccaria / Delphine Leclercq / Cyril Lafon / Jean Yves Chapelon / Khe Hoang-Xuan / Jean-Yves Delattre / Ahmed Idbaih / David Moore / Alexis Xu / Paul Schmitt / Jessica Foley / Jonathan Sukovich / Charles Cain / Aditya Pandey / Neeraj Chaudhary / Sandra Camelo-Piragua / Steven Allen / Jon Cannata / Dejan Teofilovic / Jim Bertolina / Timothy Hall / Zhen Xu / Julien Grondin / Vincent Ferrera / Gail ter Haar / Petros Mouratidis / Elizabeth Repasky / Kelsie Timbie / Lena Badr / Benjamin Campbell / John McMichael / Andrew Buckner / Jessica Prince / Aaron Stevens / Timothy Bullock / Karin Skalina / Chandan Guha / Franco Orsi / Guido Bonomo / Paolo Della Vigna / Giovanni Mauri / Gianluca Varano / George Schade / Yak-Nam Wang / Venu Pillarisetty / Joo Ha Hwang / Vera Khokhlova / Michael Bailey / Tatiana Khokhlova / Ilya Sinilshchikov / Petr Yuldashev / Yulia Andriyakhina / Wayne Kreider / Adam Maxwell / Oleg Sapozhnikov / Ari Partanen / Jonathan Lundt / Tobias Preusser / Sabrina Haase / Mario Bezzi / Jürgen Jenne / Thomas Langø / Massimo Midiri / Michael Mueller / Giora Sat / Christine Tanner / Stephan Zangos / Matthias Guenther / Andreas Melzer / Arianna Menciassi / Selene Tognarelli / Andrea Cafarelli / Alessandro Diodato / Gastone Ciuti / Sven Rothluebbers / Julia Schwaab / Jan Strehlow / Senay Mihcin / Steffen Tretbar / Thomas Payen / Carmine Palermo / Steve Sastra / Kenneth Olive / Matthew Adams / Vasant Salgaonkar / Serena Scott / Graham Sommer / Chris Diederich / Joan Vidal-Jove / Eloi Perich / Antonio Ruiz / Manuela Velat / David Melodelima / Aurelien Dupre / Jeremy Vincenot / Chen Yao / David Perol / Michel Rivoire / Samantha Tucci / Lisa Mahakian / Brett Fite / Elizabeth Ingham / Sarah Tam / Chang-il Hwang / David Tuveson / Katherine Ferrara / Stephen Scionti / Lili Chen / Dusica Cvetkovic / Xiaoming Chen / Roohi Gupta / Bin Wang / Charlie Ma / Kenneth Bader / Kevin Haworth / Christy Holland / Narendra Sanghvi / Roy Carlson / Wohsing Chen / Christian Chaussy / Stefan Thueroff / Claudio Cesana / Carlo Bellorofonte / Qingguo Wang / Han Wang / Shengping Wang / Junhai Zhang / Alberto Bazzocchi / Alessandro Napoli / Robert Staruch / Chenchen Bing / Sumbul Shaikh / Joris Nofiele / Debra Szczepanski / Michelle Wodzak Staruch / Noelle Williams / Theodore Laetsch / Rajiv Chopra / Jarrett Rosenberg / Rachelle Bitton / Suzanne LeBlang / Joshua Meyer / Mark Hurwitz / Pavel Yarmolenko / Haydar Celik / Avinash Eranki / Viktoriya Beskin / Domiciano Santos / Janish Patel / Matthew Oetgen / AeRang Kim / Peter Kim / Karun Sharma / Alexander Chisholm / Dionne Aleman / Roberto Scipione / Michael Temple / Joao Guilherme Amaral / Ruby Endre / Maria Lamberti-Pasculli / Joost de Ruiter / Fiona Campbell / Jennifer Stimec / Samit Gupta / Manoj Singh / Sevan Hopyan / Gregory Czarnota / David Brenin / Carrie Rochman / Roussanka Kovatcheva / Jordan Vlahov / Katja Zaletel / Julian Stoinov / Matthew Bucknor / Viola Rieke / Jenny Shim / Korgun Koral / Brian Lang / Carlos Wong / Heather Lam / Alexander Shinkov / Jim Hu / Xi Zhang / Jonathan Macoskey / Kimberly Ives / Gabe Owens / Hitinder Gurm / Jiaqi Shi / Matthew Pizzuto / Christopher Dillon / Ivy Christofferson / Elaine Hilas / Jill Shea / Paul Greillier / Bénédicte Ankou / Francis Bessière / Ali Zorgani / Mathieu Pioche / Wojciech Kwiecinski / Julie Magat / Sandrine Melot-Dusseau / Romain Lacoste / Bruno Quesson / Mathieu Pernot / Stefan Catheline / Philippe Chevalier / Fabrice Marquet / Pierre Bour / Fanny Vaillant / Sana Amraoui / Rémi Dubois / Philippe Ritter / Michel Haïssaguerre / Mélèze Hocini / Olivier Bernus / Pamela Tebebi / Scott Burks / Blerta Milo / Michael Gertner / Jimin Zhang / Andrew Wong / Yu Liu / Azadeh Kheirolomoom / Jai Seo / Katherine Watson / Hua Zhang / Josquin Foiret / Alexander Borowsky / Doudou Xu / Maya Thanou / Miguell Centelles / Mike Wright / Maral Amrahli / Po-Wah So / Wladyslaw Gedroyc / Esther Kneepkens / Edwin Heijman / Jochen Keupp / Steffen Weiss / Klaas Nicolay / Holger Grüll / Matthew Nagle / Anastasia V. Nikolaeva / Marina E. Terzi / Sergey A. Tsysar / Bryan Cunitz / Pierre Mourad / Matthew Downs / Georgiana Yang / Qi Wang / Johnny Chen / Justin Farry / Adam Dixon / Zhongmin Du / Ali Dhanaliwala / John Hossack / Ashish Ranjan / Danny Maples / Rachel Wardlow / Jerry Malayer / Akhilesh Ramachandran / Hirofumi Namba / Motohiro Kawasaki / Masashi Izumi / Katsuhito Kiyasu / Ryuichi Takemasa / Masahiko Ikeuchi / Takahiro Ushida / Calum Crake / Satya V. V. N. Kothapalli / Wan Leighton / Zhaorui Wang / H. Michael Gach / William Straube / Michael Altman / Young-sun Kim / Hyo Keun Lim / Hyunchul Rhim / Johanna van Breugel / Manon Braat / Chrit Moonen / Maurice van den Bosch / Mario Ries / Cristina Marrocchio / Susan Dababou / Jae Young Lee / Hyun Hoon Chung / Soo Yeon Kang / Kook Jin Kang / Keon Ho Son / Dandan Zhang / Juan Plata / Peter Jones / Aurea Pascal-Tenorio / Donna Bouley / Aaron Bond / Robert Dallapiazza / Diane Huss / Amy Warren / Scott Sperling / Ryder Gwinn / Binit Shah / W. Jeff Elias / Colleen Curley / Ying Zhang / Karina Negron / Roger Abounader / Gesthimani Samiotaki / Tsang-Wei Tu / Georgios Papadakis / Dima Hammoud / Matthew Silvestrini / Frank Wolfram / Daniel Güllmar / Juergen Reichenbach / Denis Hofmann / Joachim Böttcher / Harald Schubert / Thomas G. Lesser / Scott Almquist / Francisco Camarena / Sergio Jiménez-Gambín / Noé Jiménez / Jin Woo Chang / Vandiver Chaplin / Rebekah Griesenauer / Michael Miga / Nicholas Ellens / Raag Airan / Alfredo Quinones-Hinojosa / Keyvan Farahani / Xue Feng / Samuel Fielden / Li Zhao / Max Wintermark / Craig Meyer / Sijia Guo / Xin Lu / Jiachen Zhuo / Su Xu / Rao Gullapalli / Dheeraj Gandhi / Omer Brokman / Hongchae Baek / Hyungmin Kim / Steven Leung / Taylor Webb / Natalia Vykhodtseva / Thai-Son Nguyen / Chang Kyu Park / Sang Man Park / Na Young Jung / Min Soo Kim / Won Seok Chang / Hyun Ho Jung / Michael Plaksin / Yoni Weissler / Shy Shoham / Eitan Kimmel / Pavel B. Rosnitskiy / Steve Krupa / Eilon Hazan / Omer Naor / Yoav Levy / Noam Maimon / Inbar Brosh / Itamar Kahn / Jessica Cahill / Elodie Constanciel Colas / Adrian Wydra / Roman Maev / Amirah Aly / Ozge Sesenoglu-Laird / Linas Padegimas / Mark Cooper / Barbara Waszczak / Seruz Tehrani / Craig Slingluff / James Larner / Kumari Andarawewa / Eugene Ozhinsky / Rutwik Shah / Roland Krug / Roel Deckers / Sabine Linn / Britt Suelmann / Arjen Witkamp / Paul Vaessen / Paul van Diest / Lambertus W. Bartels / Clemens Bos / Nicolas Borys / Gert Storm / Elsken Van der Wall / Navid Farr / Moez Alnazeer / Prateek Katti / Bradford Wood / Alexis Farrer / Cyril Ferrer / Baudouin Denis de Senneville / Marijn van Stralen / Jingfei Liu / J. Kent Leach / Stephan Zidowitz / Hsin-Lun Lee / Fang-Chi Hsu / Chia-Chun Kuo / Shiu-Chen Jeng / Tung-Ho Chen / Nai-Yi Yang / Jeng-Fong Chiou / Yi-tzu Kao / Chia-Hsin Pan / Jing-Fu Wu / Yi-Chieh Tsai / Sara Johnson / Dawei Li / Ye He / Ioannis Karakitsios / Michael Schwenke / Daniel Demedts / Xu Xiao / Ian Cavin / Emilee Minalga / Robb Merrill / Rock Hadley / Pascal Ramaekers / Martijn de Greef / Kian Shahriari / Mohammad Hossein Parvizi / Kiana Asadnia / Marzieh Chamanara / Seyed Kamran Kamrava / Hamid Reza Chabok / Ruben Stein / Sébastien Muller / Jeremy Tan / Cornel Zachiu / Hans-Peter Erasmus / Glen Van Arsdell / Lee Benson / Kee W. Jang / Mary Angstadt / Bobbi Lewis / Hailey McLean / Martijn Hoogenboom / Dylan Eikelenboom / Martijn den Brok / Pieter Wesseling / Arend Heerschap / Jurgen Fütterer / Gosse Adema / Kevin Wang / Pei Zhong / Joyce Joy / Helen McLeod / Harry Kim / Matthew Lewis / Arda Ozilgen / Peter Zahos / Dezba Coughlin / Xinyan Tang / Jeff Lotz / Kathleen Jedruszczuk / Amitabh Gulati / Stephen Solomon / Elena Kaye / John Mugler / Gaetano Barbato / Gian Luca Scoarughi / Cristiano Corso / Alessandro Gorgone / Ilaria Giuseppina Migliore / Zachary Larrabee / Arik Hananel / Jean-Francois Aubry / Ayele Negussie / Emmanuel Wilson / Reza Seifabadi / Hyungwon Moon / Jeeun Kang / Changbeom Sim / Jin Ho Chang / Hyuncheol Kim / Hak Jong Lee / Noboru Sasaki / Mitsuyoshi Takiguchi / Lukas Sebeke / Xi Luo / Bram de Jager / Maurice Heemels / Christopher Abraham / Laura Curiel / Rémi Berriet / Margit Janát-Amsbury / Joseph Corea / Patrick Peiyong Ye / Ana Clauda Arias / Micheal Lustig / Bryant Svedin

Journal of Therapeutic Ultrasound, Vol 4, Iss S1, Pp 1-

2016 Volume 113

Keywords	Medical physics. Medical radiology. Nuclear medicine ; R895-920
Language	English
Publishing date	2016-11-01T00:00:00Z
Publisher	BioMed Central
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED